Trial Profile
A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ULTIMATE
- Sponsors Novartis; Novartis Pharmaceuticals
- 15 Nov 2023 Results evaluating the responsiveness of US enthesitis to SEC over 52 weeks and the correlation with clinical response of enthesitis presented at the ACR Convergence 2023
- 03 Jun 2023 Results of exploratory analysis from Phase 3B, assessing the performance of different reduced joint sets to predict response to secukinumab, compared with the 24 paired joints included in the validated GLOESS in patients with active psoriatic arthritis, presented at the 24th Annual Congress of the European League Against Rheumatism.
- 14 Nov 2022 Results to evaluate how well various reduced joint sets predict response to Secukinumab, compared with the total number of joints included in the GLOESS, presented at the ACR Convergence 2022